Daiichi sets up vaccine R&D unit in Japan

Daiichi Sankyo has established a new Tokyo-based vaccine research unit at its existing Kasai R&D Center in Japan. The move follows the April announcement that Daiichi had set up another research unit inside the National Institute of Biomedical Innovation in Osaka, where the Japanese developer says it's already conducting exploratory vaccine research and searching for new adjuvants.

Researchers at the Tokyo unit will be hunting for new vaccines for infectious diseases, according to Daiichi's release. "Now, with two vaccine research units and partnerships with organizations inside and outside of the group, Daiichi Sankyo is poised to fully realize its dedication to producing new vaccines through continuing research efforts and to supplying safe and effective existing vaccines to the healthcare professionals and other persons in Japan who are waiting for them," the pharma company said in a statement.

- see this release from Daiichi

Related Article:
Daiichi shuffles R&D programs in global restructuring

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.